An increasing number of studies have aimed to link GLUT1, GLUT3, and GLUT4 dysregulation to diabetes pathology, but results remain conflicting, likely due to differences in cell types used, patient characteristics—especially the distinct degree of obesity and different methods of treatment—and patient diagnostic criteria and thresholds of glycemic control with respect to GDM patients [5,6,7,8,9,10,35,47]. This evidence concerns the gene SLC2A1 and diabetes mellitus.